However, a significant limitation is that only 1.6% of erythrocytosis patients underwent hematology consultations, meaning that comprehensive diagnostic evaluations—including assessments of EPO levels, androgen status, and JAK2 mutation status—were not performed in most patients with baseline erythrocytosis, potentially allowing underlying hematologic conditions like PV to be included in this group; indeed, Koseoglu et al. reported that 13.3% of erythrocytosis patients were JAK2 mutation-positive [22]. The gene discussed is JAK2; the disease is polycythemia.